Results 11 to 20 of about 69,036 (281)
Current Therapeutic Research, 2020 : Background: Parkinson's disease is a neurodegenerative disorder, and a major cause of disability. Levodopa, a prodrug of dopamine, remains the gold standard in the pharmacological management of Parkinson's disease.
Benedicta Obenewaa Dankyi, MPhil +5 more
doaj +1 more source
Levodopa-responsive chorea: A review
Annals of Indian Academy of Neurology, 2020 Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj +1 more source
Sonolysis of levodopa and paracetamol in aqueous solutions. [PDF]
, 2009 Pharmaceutical products are often present in wastewater treatment effluents, rivers, lakes and, more rarely, in groundwater. The advanced oxidation methods, like ultrasound, find a promising future in the area of wastewater treatment.
Delmas, Henri +4 more
core +1 more source
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]
, 2003 Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P. +11 more
core +4 more sources
Cells, 2022 The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller +3 more
doaj +1 more source
Experience in using levodopa-benserazide
Неврология, нейропсихиатрия, психосоматика, 2015 Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina +3 more
doaj +1 more source
npj Parkinson's Disease, 2023 The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen +6 more
doaj +1 more source
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Frontiers in Neurology, 2021 Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios +9 more
doaj +1 more source
Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis [PDF]
, 2010 Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic
Bötzel, Kai +4 more
core +1 more source
Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes
Frontiers in Neurology, 2021 Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li +7 more
doaj +1 more source